Mitogen activated protein kinases as targets for development of novel anti-inflammatory drugs

Annals of the Rheumatic Diseases

Volumn 63, Issue SUPPL. 2, 2004, Pages

  Karin, M ^a  

^a San Diego   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; ANTIINFLAMMATORY AGENT; BETA INTERFERON; COLLAGENASE; I KAPPA B BETA; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN P105; PROTEIN P50; SMALL INTERFERING RNA; STRESS ACTIVATED PROTEIN KINASE; STRESS ACTIVATED PROTEIN KINASE INHIBITOR; STROMELYSIN; TOLL LIKE RECEPTOR 4; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR RELA; TRANSCRIPTION FACTOR RELB; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; CHRONIC INFLAMMATION; CONFERENCE PAPER; CYTOKINE RELEASE; DRUG TARGETING; GENE SILENCING; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; PSORIATIC ARTHRITIS; RAT; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION;

ANTI-INFLAMMATORY AGENTS; HUMANS; INFLAMMATION; MITOGEN-ACTIVATED PROTEIN KINASES;

EID: 7044274054     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2004.028274     Document Type: Conference Paper

References (34)

1. Barnes PJ, Karin M. NF-kB - a pivotal transcription foctor in chronic inflammatory diseases. New Engl J Med 1997;336:1066-71.
2. Li Q, Verma IM. NF-kB regulation in the immune system. Nat Rev Immunol 2002;2:725-34.
3. Ghosh S, Karin M. Missing pieces in the NF-kB puzzle. Cell 2002;109:S81-96.
4. Senftleben U, Cao Y, Xiao G, Greten F, Krahn G, Bonizzi G, et al. Activation by IKKa of a second, evolutionary conserved, NF-kB signaling pathway. Science 2001;293:1495-9.
5. Chen L-W, Egan L, Li Z-W, Greten FR, Kagnoff MF, Karin M. The two faces of IKK and NF-kB inhibition: prevention of systemic inflammation but increased local injury following intestinal ischemia-reperfusion. Nat Med 2003;9:575-581.
6. Banizzi G, Karin M. The two NF-kB activation pathways and their role in innate and adaptive immunity. Trends Immunol 2004;25:280-8.
7. Thanos D, Maniatis T. Virus induction of human IFNb gene expression requires the assembly of an enhanceosome. Cell 1995;83:1091-100.
8. Karin M. The regulation of AP-1 activity by mitogen-activated protein kinases. J Biol Chem 1995;270:16483-6.
9. Chang L, Karin M. Mammalian MAP kinase signaling cascades. Nature 2001;410:37-40.
10. Zhang L, Wang W, Hayashi Y, Jester JV, Birk DE, Gao M, et al. A role for MEK kinase 1 in TGF-beta/activin-induced epithelium movement and embryonic eyelid closure. EMBO J 2003;22:4443-54.
11. Dumitru CD, Ceci JD, Tsatsanis C, Kontoyiannis DKS, Lin JH, et al. TNF-a induction by LPS is regulated posttranscriptionally via a Tpl2/ERK-dependent pathway. Cell 2000;103:1073-83.
12. Medzhitov R. Toll-like receptors and innate immunity. Nat Rev Immunol 2001;1:135-45.
13. Dudley DT, Pang L, Decker SJ, Bridges AJ, Saltiel AR. A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc Natl Acad Sci USA 1995;91:7686-9.
14. Favato MF, Horiuchi KY, Manos EJ, Daulerio AJ, Stradley DA, Feeser WS, et al. Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem 1998;273:18623-32.
15. McIntyre KW, Shuster DJ, Gillooly KM, Dambach DM, Pattoli MA, Lu P, et al. A highly selective inhibitor of IkB kinase, BMS-345541, blocks bath joint inflammation and destruction in collagen-induced arthritis in mice. Arthritis Rheum 2003;48:2652-9.
16. Man Z, Boyle D, Chang L, Bennett B, Karin M, Manning A, et al. c-Jun-N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis. J Clin Invest 2001;108:73-81.
17. Hibi M, Lin A, Smeal T, Minden A, Karin M. Identification of an oncoprotein-respansive and UV-respansive protein kinase that binds and potentiates the c-Jun activation domain. Genes Dev 1993,7:2135-48.
18. Gupto S, Campbell D, Dérijard B, Davis RJ. Transcription factor ATF2: regulation by the JNK signal transduction pathway. Science 1995;267:389-93.
19. Cavigelli M, Li WW, Lin A, Su B, Yoshioka K, Karin M. The tumor promoter arsenite stimulates AP-1 activity by inhibiting a JNK phosphatose. EMBO J 1996;15:6269-79.
20. Chang L, Jones Y, Ellisman MH, Goldstein LS, Karin M. JNK1 is required for maintenance of neuronal microtubules and controls phosphorylation of microtubule-associated proteins. Dev Cell 2003;4:521-3.
21. Angel P, Karin M. The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. Biochem Biophys Acta 1991;1072:129-57.
22. Brenner DA, O'Hara M, Angel P, Chojkier M, Karin M. Prolonged activation of jun and collagenase genes by tumor necrosis factor-alpha. Nature 1989;337:661-3.
23. Hirosumi J, Tuncman G, Chang L, Gorgun CZ, Uysal KT, Maeda K, et al. A central role for JNK in obesity and insulin resistance. Nature 2002;420:333-6.
24. Freshney NW, Rawlinson L, Guesdon F, Jones E, Cowley S, Hsuan J, et al. Interleukin-1 activates a novel protein kinase cascade that results in the phosphorylation of H2927. Cell 1994;78:1039-48.
25. Man J, Lee JD, Bibbs L, et al. A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science 1994;265:808-11.
26. Lee JC, Laydon JT, McDonnell PC, Gallagher TF, Kumar S, Green D, et al. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 1994;372:739-46.
27. Nishikawa M, Myoui A, Tomita T, Takahi K, Nampei A, Yoshikawa H, et al. Prevention of the onset and progression of collagen-induced arthritis in rats by the potent p38 mitogen-activatea protein kinase inhibitor FR167653. Arthritis Rheum 2003;48:2670-81.
28. Park JM, Greten FR, Li Z-W, Karin M. Macrophage apoptosis by Anthrax Lethal Factor and p38 MAP kinase inhibition. Science 2002;297:2048-51.
29. Hsu L-C, Park JM, Zhang K, Luo J-L, Maeda S, Kaufman RJ, et al. The protein kinase PKR is required for macrophage apoptosis after activation of Toll-like receptor 4. Nature 2004;428:341-5.
30. Cerretri DP, Kozlosky CJ, Mosley B, Nelson N, Van Ness K, Greenstreet TA, et al. Molecular cloning of the interleukin-1 beta converting enzyme. Science 1992;256:97-100.
31. Thomberry NA, Bull HG, Calaycay JR, Chapman KT, Howard AD, Kostura MJ, et al. A novel heterodimeric cysteine protease is required for interleukin-1 beta processing in monocytes. Nature 1992;356:768-74.
32. Yuan J, Shaham S, Ledoux S, Ellis HM, Horvitz HR. The C. elegans cell death gene ced-3 encodes a protein similar to mammalian interleukin-1 beta-converting enzyme. Cell 1993,75:641-52.
33. Maeda S, Chang L, Li Z-W, Luo J-L, Leffert HL, Karin M. IKKb is required for prevention of apoptosis mediated by cell-bound but not by circulating TNFa. Immunity 2003;19:725-37.
34. Karin M, Lin A. NF-kB at the crossroads of life and death. Nat Immunol 2002;3:221-7.